

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of groups n = 5

## EQA round: E24/18 - Hormones 2

Dead line: 23.10.2018

RoM = robust average SD = standard deviation CV = coefficient of variation Ntot = total number of participants Nout = number of results excluded before calculation	AV = assigned value CRV = certified reference value RV = reference value CVE = consensus value from experts CVP = consensus value from all participants CVPG = consensus value from participants groups U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	Dmax = acceptable percent difference LL = lower limit UL = upper limit Neva = number of evaluated participants Nsuc = number of successful participants Srel = success (relative)
---	--	--

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(193) Ferritin</b>					119							113	104	92%
Samples and groups	[µg/L]													
<b>Sample A</b>		61,5	12	20	119							113	105	93%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		55,7	7,5	14	31	0	CVPG	57,1	1,6	24%	43,3	70,9	31	
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		47,6	4,8	10	12	0	CVPG	49,3	2,0	24%	37,4	61,2	12	
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		64,7	5,0	7,7	8	0	CVPG	63,5	2,8	24%	48,2	78,8	8	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		72,7	5,9	8,1	21	0	CVPG	73,6	1,3	24%	55,9	91,3	21	
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		59,9	8,2	14	18	0	CVPG	57,1	1,9	24%	43,3	70,9	18	
(6) IMT, IMN; (58) Beckman Coulter (Olympus)		71,9	7,6	11	6	0	CVPG	71	2,5	24%	53,9	88,1	6	
(6) IMT, IMN; (60) Roche		68,7	6,8	9,8	13	0	CVPG	70,1	2,0	24%	53,2	87	13	
Other					10	0							4	
								3x 3/25, 1x 4/40, 1x 4/149, 3x 6/1, 1x 6/179, 1x 6/999						
<b>Sample B</b>		320	59	18	119							113	111	98%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		374	27	7,3	31	0	CVPG	373	7,7	24%	283	463	31	
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		252	29	11	12	0	CVPG	255	7,0	24%	193	317	12	
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		293	36	12	8	0	CVPG	302	11	24%	229	375	8	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		346	24	7,0	21	0	CVPG	348	4,1	24%	264	432	21	
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		338	23	6,8	18	0	CVPG	330	7,0	24%	250	410	18	
(6) IMT, IMN; (58) Beckman Coulter (Olympus)		284	17	5,9	6	0	CVPG	286	4,4	24%	217	355	6	
(6) IMT, IMN; (60) Roche		267	16	6,1	13	0	CVPG	267	5,2	24%	202	332	13	
Other					10	0							4	
								3x 3/25, 1x 4/40, 1x 4/149, 3x 6/1, 1x 6/179, 1x 6/999						
<b>(320) LH</b>					101							99	95	96%
Samples and groups	[U/L]													
<b>Sample A</b>		10,4	2,0	19	101							99	97	98%
(3) FIA (FEIA, TRACE); (25) TOSOH		10,2	0,22	2,2	5	0	CVPG	9,95	0,36	15%	8,45	11,5	5	
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		9,29	0,38	4,1	24	0	CVPG	9,25	0,100	15%	7,86	10,7	24	
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		8,41	0,51	6,0	18	0	CVPG	8,72	0,16	15%	7,41	10,1	18	
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		15,3	0,82	5,3	8	0	CVPG	15,4	0,26	15%	13	17,8	8	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		12,2	0,58	4,8	27	0	CVPG	12,3	0,072	15%	10,4	14,2	27	
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		9,51	0,54	5,7	14	0	CVPG	9,44	0,15	15%	8,02	10,9	14	
Other					5	0							3	
								1x 1/36, 1x 4/40, 1x 4/149, 1x 4/164, 1x 4/999						
<b>Sample B</b>		51,1	7,6	15	101							99	97	98%
(3) FIA (FEIA, TRACE); (25) TOSOH		53,7	0,67	1,2	5	0	CVPG	50,6	4,0	15%	43	58,2	5	
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		46,6	1,8	4,0	24	0	CVPG	47	0,57	15%	39,9	54,1	24	
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		41,1	2,3	5,5	18	0	CVPG	41,2	0,77	15%	35	47,4	18	
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		88,2	14	16	8	0	CVPG	81,9	1,6	15%	69,6	94,2	8	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		54,8	1,9	3,5	27	0	CVPG	55,4	0,28	15%	47	63,8	27	
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		53,8	3,1	5,7	14	0	CVPG	52,9	0,69	15%	44,9	60,9	14	
Other					5	0							3	
								1x 1/36, 1x 4/40, 1x 4/149, 1x 4/164, 1x 4/999						
<b>(321) FSH</b>					101							99	98	99%
Samples and groups	[U/L]													
<b>Sample A</b>		92,4	21	23	101							99	99	100%
(3) FIA (FEIA, TRACE); (25) TOSOH		61,7	3,1	5,0	5	0	CVPG	62,8	3,2	15%	53,3	72,3	5	
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		92,1	6,7	7,3	25	0	CVPG	90,3	1,4	15%	76,7	104	25	
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		68,0	4,3	6,3	18	0	CVPG	68,5	1,2	15%	58,2	78,8	18	
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		103	10	9,9	8	0	CVPG	101	1,6	15%	85,8	117	8	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		93,6	4,2	4,5	26	0	CVPG	92,7	0,61	15%	78,7	107	26	
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		130	6,0	4,6	14	0	CVPG	132	1,7	15%	112	152	14	

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of groups n = 5

## EQA round: E24/18 - Hormones 2

Dead line: 23.10.2018

Test	[unit]						Comparability						N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(321) FSH</b>					101								99	98	99%
--- Samples and groups ---	[U/L]														
<b>Sample A</b>		92,4	21	23	101								99	99	100%
Other					5	0							3		
							1x 1/36, 1x 4/40, 1x 4/149, 1x 4/164, 1x 4/999								
<b>Sample B</b>		7,55	0,72	9,6	101								99	98	99%
(3) FIA (FEIA, TRACE); (25) TOSOH		7,30	0,44	6,1	5	0	CVPG	7,13	0,49	15%	6,06	8,2	5		
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		7,21	0,38	5,2	25	0	CVPG	7,15	0,094	15%	6,07	8,23	25		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		7,02	0,32	4,6	18	0	CVPG	7,07	0,12	15%	6	8,14	18		
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		7,70	1,0	13	8	0	CVPG	7,68	0,082	15%	6,52	8,84	8		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		7,59	0,30	3,9	26	0	CVPG	7,58	0,050	15%	6,44	8,72	26		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		9,60	0,45	4,7	14	0	CVPG	9,78	0,13	15%	8,31	11,3	14		
Other					5	0							3		
							1x 1/36, 1x 4/40, 1x 4/149, 1x 4/164, 1x 4/999								
<b>(322) Prolactin</b>					109								106	101	95%
--- Samples and groups ---	[mU/L]														
<b>Sample A</b>		244	34	14	109								106	103	97%
(3) FIA (FEIA, TRACE); (25) TOSOH		297	14	4,8	6	0	CVPG	259	35	16%	217	301	6		
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		245	11	4,6	27	0	CVPG	247	3,1	16%	207	287	27		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		228	16	6,8	18	0	CVPG	231	4,3	16%	194	268	18		
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		214	20	9,4	9	0	CVPG	219	3,7	16%	183	255	9		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		273	11	4,1	30	0	CVPG	270	1,8	16%	226	314	30		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		201	7,0	3,5	14	0	CVPG	203	2,4	16%	170	236	14		
Other					5	0							2		
							1x 1/36, 1x 4/40, 1x 4/149, 1x 4/164, 1x 4/999								
<b>Sample B</b>		726	54	7,4	109								106	102	96%
(3) FIA (FEIA, TRACE); (25) TOSOH		874	22	2,6	6	0	CVPG	759	120	16%	637	881	6		
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		742	37	5,0	27	0	CVPG	754	10,0	16%	633	875	27		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		676	46	6,8	18	0	CVPG	688	13	16%	577	799	18		
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		726	31	4,3	9	0	CVPG	727	12	16%	610	844	9		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		755	32	4,2	30	0	CVPG	750	5,4	16%	630	870	30		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		668	24	3,5	14	0	CVPG	670	10	16%	562	778	14		
Other					5	0							2		
							1x 1/36, 1x 4/40, 1x 4/149, 1x 4/164, 1x 4/999								
<b>(325) Insulin</b>					29								27	27	100%
--- Samples and groups ---	[mU/L]														
<b>Sample A</b>		21,1	3,6	17	29								27	27	100%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		17,3	0,59	3,4	5	0	CVPG	17,5	0,22	20%	14	21	5		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		18,0	0,37	2,1	5	0	CVPG	17,7	0,61	20%	14,1	21,3	5		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		24,1	1,4	5,8	11	0	CVPG	24,1	0,24	20%	19,2	29	11		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		21,1	2,4	11	6	0	CVPG	21,5	0,54	20%	17,2	25,8	6		
Other					2	0							0		
							1x 1/12, 1x 3/25								
<b>Sample B</b>		122	19	16	29								27	27	100%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		98,6	2,4	2,4	5	0	CVPG	98,3	1,0	20%	78,6	118	5		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		107	8,2	7,7	5	0	CVPG	109	3,7	20%	87,2	131	5		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		137	8,2	5,9	11	0	CVPG	136	1,2	20%	108	164	11		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		122	7,6	6,2	6	0	CVPG	122	3,4	20%	97,6	147	6		
Other					2	0							0		
							1x 1/12, 1x 3/25								
<b>(326) Folate</b>					117								114	112	98%
--- Samples and groups ---	[nmol/L]														
<b>Sample A</b>		47,9	8,2	17	117								114	112	98%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		55,8	6,0	11	34	0	CVPG	54,7	1,5	27%	39,9	69,5	34		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		46,0	1,6	3,5	15	0	CVPG	46,9	0,67	27%	34,2	59,6	15		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		42,0	3,0	7,2	43	0	CVPG	41,9	0,44	27%	30,5	53,3	43		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		53,4	2,5	4,7	17	0	CVPG	52	0,98	27%	37,9	66,1	17		

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of groups n = 5

## EQA round: E24/18 - Hormones 2

Dead line: 23.10.2018

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(326) Folate</b>					117							114	112	98%
Samples and groups	[nmol/L]													
<b>Sample A</b>		47,9	8,2	17	117							114	112	98%
Other					8	0						5		
							2x 3/25, 4x 4/29, 1x 4/40, 1x 4/149							
<b>Sample B</b>		33,8	7,2	21	117							114	113	99%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		40,7	2,1	5,0	34	0	CVPG	40,3	0,54	27%	29,4	51,2	34	
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		31,1	1,4	4,6	15	0	CVPG	31,4	0,50	27%	22,9	39,9	15	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		27,9	2,0	7,1	43	0	CVPG	27	0,29	27%	19,7	34,3	43	
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		39,9	2,2	5,5	17	0	CVPG	38,1	0,80	27%	27,8	48,4	17	
Other					8	0						5		
							2x 3/25, 4x 4/29, 1x 4/40, 1x 4/149							
<b>(327) Vitamin B12</b>					103							100	95	95%
Samples and groups	[pmol/L]													
<b>Sample A</b>		218	33	15	103							100	95	95%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		216	13	6,2	27	0	CVPG	216	3,8	20%	172	260	27	
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		165	13	7,7	15	0	CVPG	166	3,8	20%	132	200	15	
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		203	27	13	5	0	CVPG	205	10	20%	164	246	5	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		242	17	6,9	39	0	CVPG	239	2,3	20%	191	287	39	
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		210	32	15	13	0	CVPG	214	5,5	20%	171	257	13	
Other					4	0						1		
							2x 3/25, 1x 4/40, 1x 4/149							
<b>Sample B</b>		691	66	9,6	103							100	100	100%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		691	39	5,6	27	0	CVPG	690	10	20%	552	828	27	
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		573	28	4,9	15	0	CVPG	579	13	20%	463	695	15	
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		631	14	2,2	5	0	CVPG	687	24	20%	549	825	5	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		733	31	4,3	39	0	CVPG	725	4,5	20%	580	870	39	
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		687	46	6,7	13	0	CVPG	683	12	20%	546	820	13	
Other					4	0						1		
							2x 3/25, 1x 4/40, 1x 4/149							
<b>(328) hGH</b>					21							20	16	80%
Samples and groups	[mU/L]													
<b>Sample A</b>		9,95	1,1	11	21							20	17	85%
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		10,3	0,97	9,4	8	0	CVPG	10,8	0,21	19%	8,74	12,9	8	
Other					13	0						12		
							2x 1/36, 1x 3/25, 2x 4/12, 4x 4/60, 4x 4/164							
<b>Sample B</b>		38,1	4,3	11	21							20	17	85%
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		37,9	2,3	6,2	8	0	CVPG	38,6	0,64	19%	31,2	46	8	
Other					13	0						12		
							2x 1/36, 1x 3/25, 2x 4/12, 4x 4/60, 4x 4/164							
<b>(329) IGF-1</b>					22							21	18	86%
Samples and groups	[µg/L]													
<b>Sample A</b>		219	53	24	22							21	20	95%
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		181	19	11	10	0	CVPG	176	3,5	22%	137	215	10	
(4) LIA (CLIA, CMIA, ECLIA); (164) DiaSorin		289	31	11	7	0	CVPG	263	9,1	22%	205	321	7	
Other					5	0						4		
							1x 1/36, 1x 2/999, 3x 4/60							
<b>Sample B</b>		320	55	17	22							21	19	90%
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		301	34	11	10	0	CVPG	291	6,3	22%	226	356	10	
(4) LIA (CLIA, CMIA, ECLIA); (164) DiaSorin		381	57	15	7	0	CVPG	347	13	22%	270	424	7	
Other					5	0						4		
							1x 1/36, 1x 2/999, 3x 4/60							
<b>(390) Renin</b>					16							15	14	93%
Samples and groups	[ng/L]													
<b>Sample A</b>		36,3	4,9	14	16							15	14	93%
(1) RIA (IRMA); (185) Cisbio		32,4	1,8	5,5	6	0	CVPG	31,3	1,7	20%	25	37,6	6	
(4) LIA (CLIA, CMIA, ECLIA); (164) DiaSorin		38,1	2,0	5,3	6	0	CVPG	35,1	0,85	20%	28	42,2	6	
Other					4	0						3		
							1x 2/66, 3x 4/183							
<b>Sample B</b>		36,1	5,2	14	16							15	14	93%
(1) RIA (IRMA); (185) Cisbio		32,3	2,9	9,0	6	0	CVPG	31,1	1,6	20%	24,8	37,4	6	

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of groups n = 5

## EQA round: E24/18 - Hormones 2

Dead line: 23.10.2018

Test	[unit]						Comparability						N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(390) Renin</b>					16								15	14	93%
Samples and groups	[ng/L]														
<b>Sample B</b>		36,1	5,2	14	16								15	14	93%
(4) LIA (CLIA, CMIA, ECLIA); (164) DiaSorin		36,7	4,5	12	6	0	CVPG	35,1	0,84	20%	28	42,2	6		
Other					4	0							3		
															1x 2/66, 3x 4/183
<b>(392) IGF-BP3</b>					7								6	6	100%
Samples and groups	[µg/L]														
<b>Sample A</b>		4050	690	17	7								6	6	100%
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		4160	530	13	5	0	CVPG	4220	94	20%	3370	5070	5		
Other					2	0							1		
															1x 1/36, 1x 1/66
<b>Sample B</b>		4250	840	20	7								6	6	100%
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		4460	530	12	5	0	CVPG	4150	82	20%	3320	4980	5		
Other					2	0							1		
															1x 1/36, 1x 1/66
<b>(393) C-peptide</b>					111								106	106	100%
Samples and groups	[pmol/L]														
<b>Sample A</b>		264	64	24	111								106	106	100%
(3) FIA (FEIA, TRACE); (25) TOSOH		191	16	8,5	9	0	CVPG	191	20	20%	152	230	9		
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		251	16	6,2	26	0	CVPG	250	7,5	20%	200	300	26		
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		202	8,7	4,3	16	0	CVPG	202	5,1	20%	161	243	16		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		329	13	3,9	41	0	CVPG	328	4,7	20%	262	394	41		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		211	9,9	4,7	14	0	CVPG	210	6,7	20%	168	252	14		
Other					5	0							0		
															1x 1/12, 2x 1/36, 1x 3/179, 1x 4/164
<b>Sample B</b>		262	65	25	111								106	106	100%
(3) FIA (FEIA, TRACE); (25) TOSOH		188	11	5,6	9	0	CVPG	188	13	20%	150	226	9		
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		249	13	5,4	26	0	CVPG	248	6,5	20%	198	298	26		
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		202	13	6,2	16	0	CVPG	202	7,6	20%	161	243	16		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		328	13	3,9	41	0	CVPG	327	4,8	20%	261	393	41		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		209	12	5,8	14	0	CVPG	208	7,4	20%	166	250	14		
Other					5	0							0		
															1x 1/12, 2x 1/36, 1x 3/179, 1x 4/164
<b>(394) SHBG</b>					53								50	47	94%
Samples and groups	[nmol/L]														
<b>Sample A</b>		29,4	3,5	12	53								50	48	96%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		27,7	3,3	12	12	0	CVPG	28,2	0,65	20%	22,5	33,9	12		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		27,6	2,1	7,8	8	0	CVPG	27,8	0,84	20%	22,2	33,4	8		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		32,4	1,8	5,5	16	0	CVPG	32	0,28	20%	25,6	38,4	16		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		27,9	2,0	7,3	10	0	CVPG	27,4	0,41	20%	21,9	32,9	10		
Other					7	0							4		
															1x 1/36, 1x 3/25, 4x 4/29, 1x 4/999
<b>Sample B</b>		29,5	3,4	11	53								50	48	96%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		28,1	1,8	6,3	12	0	CVPG	28	0,66	20%	22,4	33,6	12		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		26,7	3,5	13	8	0	CVPG	27,1	0,97	20%	21,6	32,6	8		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		32,2	1,7	5,2	16	0	CVPG	31,9	0,26	20%	25,5	38,3	16		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		28,8	2,8	9,8	10	0	CVPG	27,5	0,53	20%	22	33	10		
Other					7	0							4		
															1x 1/36, 1x 3/25, 4x 4/29, 1x 4/999
<b>(405) Parathyroid hormone (PTH)</b>					52								50	46	92%
Samples and groups	[pmol/L]														
<b>Sample A</b>		0,825	0,34	41	52								50	46	92%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		1,21	0,16	13	6	0	CVPG	1,22	0,047	23%	0,939	1,51	6		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		0,607	0,039	6,4	11	0	CVPG	0,668	0,031±0,276	0,392	0,944		11		
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		0,540	0,33	60	5	0	CVPG	0,422	0,068±0,276	0,146	0,698		5		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		1,06	0,13	13	18	0	CVPG	1,06	0,022±0,28	0,784	1,34		18		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		0,574	0,16	29	10	0	CVPG	0,53	0,046±0,276	0,254	0,806		10		

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of groups n = 5

## EQA round: E24/18 - Hormones 2

Dead line: 23.10.2018

Test	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability								
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(405) Parathyroid hormone (PTH)</b>					52							50	46	92%	
Samples and groups															
<b>Sample A</b>	[pmol/L]	0,825	0,34	41	52							50	46	92%	
Other					2	0						0			
							1x 3/25, 1x 6/999								
<b>Sample B</b>		9,88	2,1	21	52							50	49	98%	
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		12,5	1,3	11	6	0	CVPG	12,5	0,34	23%	9,62	15,4	6		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		8,97	0,73	8,2	11	0	CVPG	9,56	0,38	23%	7,36	11,8	11		
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		13,0	0,59	4,6	5	0	CVPG	13,1	0,46	23%	10	16,2	5		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		8,29	0,54	6,5	18	0	CVPG	8,08	0,089	23%	6,22	9,94	18		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		10,3	0,55	5,4	10	0	CVPG	10,2	0,25	23%	7,85	12,6	10		
Other					2	0							0		
							1x 3/25, 1x 6/999								
<b>(407) Parathyroid hormone (PTH 1-84)</b>					26							25	22	88%	
Samples and groups															
<b>Sample A</b>	[pmol/L]	0,850	0,20	23	26							25	22	88%	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		0,883	0,16	18	21	0	CVPG	0,883	0,085 ± 0,207	0,679	1,09	21			
Other					5	0						4			
							1x 3/60, 4x 4/164								
<b>Sample B</b>		7,97	0,62	7,8	26							25	25	100%	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		8,11	0,42	5,2	21	0	CVPG	8,11	0,22	17%	6,73	9,49	21		
Other					5	0						4			
							1x 3/60, 4x 4/164								

st\_kn\_p

End of report

Printed: 05.11.2018